TB-500: what the research actually says

TB-500 almost never appears on its own. It's usually mentioned in the same breath as BPC-157, marketed as a recovery "stack" for injuries. As with BPC-157, the marketing has outrun the science, and it's worth separating the two clearly.

What TB-500 is

TB-500 is sold as a synthetic version of a portion of Thymosin Beta-4 (often written Tβ4), a small protein naturally present in nearly all human and animal cells, where it's involved in cell movement, blood vessel formation, and wound repair.² It's important to note a distinction that gets blurred in marketing: most of the published research is on native thymosin beta-4 or lab-engineered thymosin-beta-4 variants, not necessarily on an identical product to what's sold commercially as "TB-500."

What the evidence shows — and where it stops

Recent peer-reviewed studies on thymosin beta-4 and its engineered variants are almost entirely preclinical: cell-culture and animal models of diabetic wound healing, corneal repair, and fat-graft survival.² These are legitimate, published findings, but they describe what happens in mice, rats, or lab dishes, not in people.

There are essentially no published controlled human clinical trials of TB-500 establishing that it speeds healing, improves recovery, or is safe at any dose in humans. As with most peptides in this category, "shows an effect in a rodent wound model" and "shown to work in people" are two very different claims, and only the first one is currently backed by data.

Regulatory status

TB-500 is not an FDA-approved drug for any use. It sits in the same regulatory gray zone as BPC-157: unapproved peptides sold as "research use only" fall outside the manufacturing, purity, and safety oversight that applies to compounded or FDA-approved medications.¹ In practice, that means there's no requirement that a vial labeled TB-500 actually contains what it claims, at the concentration it claims, free of contaminants.

TB-500 vs. BPC-157

The two are frequently stacked together specifically because their marketing claims overlap. Read the dedicated breakdown on BPC-157 for the FDA's 2023 compounding action, which applies to that molecule specifically.

"Unfortunately, there just isn't enough valuable, statistically significant evidence that points us to be able to recommend them safely."

— Dr. Anthony C. Tam, MD, family and sports medicine physician, Henry Ford Health, discussing newer injectable peptides marketed for recovery and muscle growth, in the American Medical Association (April 2026)

What's actually known about safety

Because human trials don't exist, there's no established human dosing, no data on drug interactions, and no long-term safety record for TB-500. Whatever is in a specific vial depends entirely on the manufacturer, and "research use only" products carry no verification that the contents match the label. That combination, unverified product plus self-injection with no medical oversight, is where most real-world harm in this category comes from, not necessarily the molecule itself.

If you're considering it anyway

The same guidance applies here as for any unapproved peptide: a licensed clinician can tell you honestly what human evidence does and doesn't exist, and only a licensed pharmacy channel has any quality control at all. Our safest way to try peptides guide covers how to vet a provider.